Slide 1: Q3 2021 Results Presentation
Q3 2021 Results Presentation Dietmar Siemssen, CEO Bernd Metzner, CFO Duesseldorf, October 12, 2021
Slide 2: Disclaimer
Disclaimer − This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: Well Underway: Innovative Solutions Provider
Well Underway: Innovative Solutions Provider CEO Dietmar Siemssen
Slide 4: Transforming Gerresheimer into a growth company as innovation leader and solution provider
Transforming our Gerresheimer into a growth company as innovation leader and solution provider 201 5
Slide 5: Successful on the Sustainable Growth Path
Successful on the Sustainable Growth Path Key Take-Aways Q3 2021 High Single Digit Growth: Boosting Sustain growth Org. revenue growth: High Value Solutions: momentum Adj. EBITDA margin: +9.8% core 1 ~ +30% yoy in the 20.9% core1 (FXN) +10.0% group fourth quarter – Adj. EPS: Biologics: +30% yoy +5.2
Slide 6: New Gerresheimer: Growth Along the Whole Portfolio
New Gerresheimer: Growth Along the Whole Portfolio Leveraging Growth With the Right Product Solutions High Value Solutions Global mega trends, e.g. biologics, Biological Solutions boosting growth of High Value Solutions Pharma Solutions/ Regional expansion balancing the global Underlying Business fo
Slide 7: Leverage Beauty Solutions With our Pharma Skills
Leverage Beauty Solutions With our Pharma Skills Deep Dive Beauty Solutions: Cosmetic Goes Health Examples for anticipating global beauty trends through pharma expertise Smart Injectables High Value Irradiated bottles & Pen systems Devices Pharma Glass “back” system HEALTHCARE Holistic approach Surg
Slide 8: Innovate on Solutions to Enlarge Beauty Portfolio
Innovate on Solutions to Enlarge Beauty Portfolio Cosmetics and Beauty Growth Opportunities in Tubular, Moulded and Plastics Beauty Solutions in Tubular Selective Segment Sustainability & Beauty − Newly developed pipettes as − Premium options offer − Gx positioned as leading holistic solution in a r
Slide 9: Innovative Solutions Provider: Well Underway
Innovative Solutions Provider: Well Underway Continuously Enhancing our Portfolio Offering by Best Solutions and Platforms Gerresheimer is a Innovation as key growth driver growth company as innovation leader and solution provider Continue to innovate: own products with own IP Strategic partnerships
Slide 10: Strong Q3 2021 – Financial Update
Strong Q3 2021 – Financial Update CFO Dr. Bernd Metzner
Slide 11: Q3 2021: Revenue Growth Accelerated
Q3 2021: Revenue Growth Accelerated Operational View on key KPIs Revenues Adj. EBITDA Adj. EPS (in EUR m) (in EUR m) (in EUR) organic growth yoy 3.5% organic growth yoy organic growth 9.8% core business: 5.2% core business: yoy: Adj. EBITDA margin core 20.9% 382 (FXN): 75 75 0.97 0.97 349 381 1.01 7
Slide 12: Strong Positions Provide Pricing Power
Strong Positions Provide Pricing Power Q3 2021 Adj. EBITDA Margin Reconciliation in Gx Core Business (in %) +0.8 23.0 22.2 ~1.5 20.9 0.6 Q3 2021 Q3 Subsequent Q3 2021 Q3 2020 FX-neutral Quarters FX-neutral FX-neutral Pro-forma Pass-Through Effects Timing Effects − Direct pass-through of raw and − Q3
Slide 13: Strong Sales Performance in Core Business
Strong Sales Performance in Core Business Q3 2021: Divisional Performance and Highlights Organic yoy & margin In EUR m Revenues Adj. EBITDA Strong growth in the segment +8.0% -0.8% — Strong organic revenue growth supported by 208 pass-through of increasing raw material cost P&D 194 52 51 — Adj. EBIT
Slide 14: Good Free Cashflow Performance
Good Free Cashflow Performance Cash Flow and Financial Debt In EUR m Q3 2021 Q3 2020 Change Comments Adjusted EBITDA 74.8 75.0 -0.2 EUR ~ -1m negative FX effects Change in net working capital 23.9 4.7 19.2 Strong improvement of net working capital Net interest paid -2.0 -2.3 0.3 Net taxes paid -8.6
Slide 15: 2021 Outlook: Guidance Confirmed
2021 Outlook: Guidance Confirmed CEO Dietmar Siemssen
Slide 16: Guidance Confirmed: Accelerated Revenue Growth
Guidance Confirmed: Accelerated Revenue Growth Q4 2021 Projection and Outlook Mid-to high-single digit Double-digit revenue organic revenue growth Primary growth expected expected Plastics & Packaging Devices Glass Gx Strong revenue Growth from plastics Biological contribution from both business as
Slide 17: Profitable Growth Accelerating
Profitable Growth Accelerating Guidance Confirmed – Focus on Absolute Adj. EBITDA Targets For Core Business1 (FXN) FY 2021 Mid-term Accelerate Mid-single High-single Revenue growth digit growth digit growth Further expand ~ 22 to 23% ~ 23% Adj. EBITDA margin Drive Adj. EPS growth ≥ 10% ≥ 10% p.a. an
Slide 18: Appendix
Appendix 18 10/12/2021 Q3 2021 Earnings Presentation
Slide 19: Financial Calendar
Financial Calendar Publication Financial Publication 1st Publication 2nd Year 2021 Results Quarter Results 2022 Quarter Results 2022 February April July 17, 2022 7, 2022 13, 2022 19 10/12/2021 Q3 2021 Earnings Presentation
Slide 20: Q3 Revenue & Organic Growth Reconciliation
Q3 Revenue & Organic Growth Reconciliation (1 of 4) in EUR m organic growth +10.0% 381.0 1.0 382.0 0.9 -0.3 18.8 349.2 346.3 15.3 -2.9 +12.2% +8.0% Revenue FX Revenue Q3 P&D PPG GAT HQ, Cons. Revenue Q3 FX Revenue Q3 2020 2020 (FXN) 2021 (FXN) Q3 2021 +9.8% 380.8 1.0 381.8 18.8 349.5 346.7 15.3 -2.9
Slide 21: YTD Revenue & Organic Growth Reconciliation
YTD Revenue & Organic Growth Reconciliation (2 of 4) in EUR m organic growth +7.3% 1,064.0 1,061.9 2.6 1.3 -2.1 39.5 1,016.0 -24.0 991.9 28.5 +8.7% +5.3% Revenue FX Revenue 9M P&D PPG GAT HQ, Cons. Revenue 9M FX Revenue 9M 2020 2020 (FXN) 2021 (FXN) 9M 2021 +6.9% 1,061.1 1,059.0 -2.1 39.5 1,017.1 -2
Slide 22: Q3 EBITDA & Organic Growth Reconciliation
Q3 EBITDA & Organic Growth Reconciliation (3 of 4) in EUR m organic growth & margin +2.1% -1.2 -0.4 75.6 75.0 3.5 74.8 -0.9 74.1 -0.8 -0.4 -0.8% +11.1% +21.4% +19.9% Adj. EBITDA FX Adj. P&D PPG GAT HQ, Cons. Adj. FX Adj. EBITDA Q3 2020 EBITDA Q3 EBITDA Q3 Q3 2021 2020 (FXN) 2021 (FXN) +3.5% -0.4 79.
Slide 23: YTD EBITDA & Organic Growth Reconciliation
YTD EBITDA & Organic Growth Reconciliation (4 of 4) in EUR m organic growth & margin +4.6% 214.0 2.4 210.9 210.2 0.4 3.7 -3.1 -5.8 204.5 3.0 2.2% +3.9% +20.6% +20.1% Adj. EBITDA FX Adj. P&D PPG GAT HQ, Cons. Adj. FX Adj. EBITDA 9M 2020 EBITDA 9M EBITDA 9M 9M 2021 2020 (FXN) 2021 (FXN) +4.2% 224.0 2.
Slide 24: Financial Headroom
Financial Headroom Net Financial Debt & Adjusted EBITDA Leverage Net financial debt according to credit agreement in force Maturity Profile In EUR m Net financial debt 1,018 (In EUR m)1 981 Promissory loans RCF 3.3 Adj. EBITDA leverage (x) 3.2 476 Aug-20 Aug-21 In EUR m Q3 2021 Q3 2020 Drawn portion
Slide 25: Reconciliation Q3 2021
Reconciliation Q3 2021 Reported and Adjusted Financials on Group Level Q3 2021 Q3 2020 Organic growth YoY1 In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 382.0 382.0 349.2 10.0% EBITDA 69.1 5.7 74.8 75.0 2.1% Depreciation & -34.7 8.7 -26.0 -26.3 Amortization EBIT 34.4 14.4 48.8 48.
Slide 26: Reconciliation 9M 2021
Reconciliation 9M 2021 Reported and Adjusted Financials 9M 2021 9M 2020 Organic growth YoY1 In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 1,061.9 1,061.9 1,016.0 7.3% EBITDA 196.4 14.5 210.9 210.2 4.6% Depreciation & -100.5 26.6 -73.9 -80.8 Amortization EBIT 95.9 41.1 137.0 129.4
Slide 27: Capex Burdening FCF Performance
Capex Burdening FCF Performance Cash Flow and Financial Debt In EUR m 9M 2021 9M 2020 Change Comments Adjusted EBITDA 210.9 210.2 0.6 EUR ~ -3 m negative FX effects Change in net working capital -54.3 -71.0 16.7 Strong working capital improvement Net interest paid -5.9 -7.0 1.0 Q2 20 driven by one-t
Slide 28: Gerresheimer – innovating for a better life
serresheimer innovating for a better life